ClinicalTrials.gg
CompletedNCT00706589Updated Jul 26, 2013Results posted

Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

A Phase 3 interventional study of aripiprazole and placebo in Chronic Motor or Vocal Tic Disorder and Tourette's Disorder, sponsored by Korea Otsuka Pharmaceutical Co., Ltd.. Completed at 6 sites in Korea, Republic of. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2013-07-26.

Primary conditionTourette SyndromeRegistry: Tic DisordersReclassifiedWhy we changed it
Registry
Tic Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tourette Syndrome
Why
  1. The study's listed conditions name Tourette Syndrome, a narrower term within Tic Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Korea Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing aripiprazole in Tourette Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Tourette Syndrome.

Enrollment
7th of 10
61 · median 97
Started
2008
the only one that year
Phase 3
7 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Korea Otsuka Pharmaceutical Co., Ltd.

Among the 10 studies testing aripiprazole in Tourette Syndrome, this one is the 7th largest by enrollment, is the only one that started in 2008, is one of 7 in phase 3, and was the 3rd registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

None of the 10 studies testing aripiprazole in Tourette Syndrome is open now. The open studies under Tourette Syndrome, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing aripiprazole in Tourette Syndrome as a file.
02

Study summary

The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6\~18 years with chronic tic disorders or Tourette's disorder

03

Conditions studied

  • Chronic Motor or Vocal Tic Disorder
  • Tourette's Disorder

Browse trials for

Keywords

  • Chronic Motor Tic disorder
  • Chronic Phonic Tic disorder
  • Tourette's disorder
  • Aripiprazole
  • Abilify
  • Children
  • Adolescent
04

In context

Tourette Syndrome Reclassified

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

This study's enrollment of 61 is above the median of 36 across 183 interventional studies indexed under Tourette Syndrome.

Browse Tourette Syndrome studies →

Lead sponsor

Korea Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 42 studies on the registry; 3 are open to participants now.

Compared within Tourette Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tic Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who can provide an assent form signed by themselves and form by their legal representatives prior to performing of any study procedures.
  2. Male or female children and adolescents aged 6 to 18 years
  3. Patients who are diagnosed with chronic tic disorders(Motor or Phonic) or Tourette's disorder according to (Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition)(using K-SADS-PL-K (Kiddle-Schedule for Affective Disorders and Schizophrenia,Present and Lifetime Version-Korean version)) and require drug therapy.
  4. The total tic score of the K-YGTSS (Korean version of Yale Global Tic Severity Scale)is more than 22 at baseline

Exclusion criteria

Exclusion Criteria:

  1. Patients with secondary tic symptoms accompanied by Tardive tics, Huntington disease, neuroacanthocytosis, mental retardation, or autism
  2. Patients with IQ (Intelligence quotient) (assessed using KEDI-WISC (Korean educational Development Institute-Wechsler Intelligence Scale for children)) 70 and lower than 70
  3. Patients with a history of neuroleptic malignant syndrome
  4. Patients with antipsychotic or alcohol use disorder (abuse, dependence, and/or withdrawal) according to criteria for the past 3 months
  5. Patients with a history of allergy or reaction to aripiprazole
  6. Patients with a history of resistance to treatment with antipsychotics
  7. Patients who have participated in another clinical study within 1 month prior to screening
  8. Patients who have previously taken aripiprazole or participated in a clinical study with aripiprazole
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    1

    Aripiprazole 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)

    Drug: aripiprazole

  • Placebo comparator
    2

    Placebo 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)

    Drug: placebo

Interventions

  • Initial dose : 2mg, Maximum dose : 20mg

    Also known as: Abilify

  • Drugplacebo

    Initial dose: 2mg, Maximum dose:20mg

07

What researchers measure

Primary outcomes

  1. Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)

    The meaning of the total tic scores is a sum of the total motor tic score and total phonic tic score and the total tic score will be indicated from zero point to 50 points. And also, for the global tic severity scale is sum of the total tic scores and impairment score and it will be indicated from zero point to 100 points. Additionally, for the imparment score is also indicated from zero to 50 points same as total tic scores. And it is divided as 0 point, 10 point, 20 point and etc... Lastly, someone who gets a high score, it will be considered worse result.

    Time frame: 10 week

Secondary outcomes

  1. 1)Percent Change of Total Tic Scores on the Korean Version of YaleGlobalTicseverity Scale.2)Response Rate Assessed With the Tic Score ClinicalGlobalImpressionImprovementScale.3)Mean Change in Scores on the Tic Score ClinicalGlobal ImpressionSeverityScale.

    Time frame: 10 weeks

08

Results

Posted Jul 26, 2013

Participant flow

Recruitment period :Aug2008\~Jan2010 Types of location: Medical Center

Participant flow — Overall Study
MilestoneAripiprazolePlacebo
Started3229
Completed2925
Not completed34

Outcome measures

Secondary1)Percent Change of Total Tic Scores on the Korean Version of YaleGlobalTicseverity Scale.2)Response Rate Assessed With the Tic Score ClinicalGlobalImpressionImprovementScale.3)Mean Change in Scores on the Tic Score ClinicalGlobal ImpressionSeverityScale.
Time frame:
10 weeks
Reported as:
Mean · participants

Results for this outcome have not been posted.

PrimaryMean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)

The meaning of the total tic scores is a sum of the total motor tic score and total phonic tic score and the total tic score will be indicated from zero point to 50 points. And also, for the global tic severity scale is sum of the total tic scores and impairment score and it will be indicated from zero point to 100 points. Additionally, for the imparment score is also indicated from zero to 50 points same as total tic scores. And it is divided as 0 point, 10 point, 20 point and etc... Lastly, someone who gets a high score, it will be considered worse result.

Time frame:
10 week
Reported as:
Mean · units on a scale
Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)
units on a scaleAripiprazolePlacebo
Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)-9.62 (-32 to 8)-14.97 (-33 to 2)

Adverse events

Collected over 14 week. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole—0/32 (0%)24/32 (75%)
Placebo—0/28 (0%)20/28 (71.4%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAripiprazolePlacebo
NauseaGastrointestinal disorders6/322/28
HeadacheNervous system disorders5/321/28
AkathisiaNervous system disorders2/324/28
DizzinessNervous system disorders1/324/28
SedationNervous system disorders4/323/28
SomnolenceNervous system disorders4/320/28
NasopharyngitisInfections and infestations4/320/28
VomitingGastrointestinal disorders0/323/28
InsomniaPsychiatric disorders0/323/28
Extrapyramidal disorderNervous system disorders3/322/28

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AripiprazolePlaceboTotal
<=18 years322961
Between 18 and 65 years000
>=65 years000
Age Continuous
Age Continuous(years)AripiprazolePlaceboTotal
Mean10.97 ± 2.4910.93 ± 3.0010.95 ± 2.72
Sex: Female, Male
Sex: Female, Male(Participants)AripiprazolePlaceboTotal
Female268
Male302353
Region of Enrollment
Region of Enrollment(participants)AripiprazolePlaceboTotal
Korea, Republic of322961
09

Study locations

6 sites
  • Inha University Hospital
    Inchon, 400-711, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
  • Yonsei University Severance Hospital
    Seoul, 120-752, Korea, Republic of
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Asan Medical Center
    Seoul, 138-736, Korea, Republic of
  • Chung-Ang Univ. Medical center
    Seoul, 156-755, Korea, Republic of
10

References and documents

Publications

  • Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, Kim BN, Cho SC. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry. 2013 Aug;74(8):e772-80. doi: 10.4088/JCP.12m08189. PubMed 24021518 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2008
First posted
Jun 27, 2008
Start
Oct 2008
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Jul 26, 2013
Last update
Jul 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00706589
Responsible party
Sponsor
First posted
Jun 27, 2008
Start date
Oct 2008
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Jul 26, 2013
Last update
Jul 26, 2013

Study contacts

Soochurl Cho, MD. Ph.D
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion